Neola Medical AB (SE:NEOLA)
:NEOLA
Want to see SE:NEOLA full AI Analyst Report?
NEOLA Stock Chart & Stats
kr1.08
kr0.08(3.31%)
At close: 4:00 PM EST
kr1.08
kr0.08(3.31%)
Day’s Range― - ―
52-Week Rangekr0.58 - kr2.94
Previous CloseN/A
Volume18.12K
Average Volume (3M)12.79K
Market Cap
kr122.23M
Enterprise Valuekr64.69M
Total Cash (Recent Filing)kr16.12M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.35
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding124,720,375
10 Day Avg. Volume10,323
30 Day Avg. Volume12,794
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.07
Price to Sales (P/S)0.00
P/FCF Ratio-3.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr9.10M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt and a meaningful equity base (~SEK 75.8M) materially reduce refinancing and solvency risk. This gives management flexibility to fund clinical validation and commercialization over the coming months without immediate borrowing, supporting operational durability while revenues scale.
Structural Market OpportunityNon-invasive vital-sign monitoring addresses enduring clinical priorities—patient comfort, infection risk reduction, and continuous monitoring. These structural demands across hospitals and care facilities support long-term adoption potential for a validated sensor system, independent of short-term market cycles.
Controlled Cash Burn TrendWhile operating cash flow is negative, the burn rate has remained relatively stable rather than accelerating. That controlled spending pattern extends runway provided current equity, allowing incremental R&D and commercialization milestones to be pursued without immediate capital shock if financing windows are accessible.
Bears Say
No Revenue / Persistent LossesMulti-year absence of material revenue indicates the product is still pre-commercial or has failed to achieve traction. Persistent losses erode capital and make future growth contingent on successful commercialization or recurring financing, creating structural execution risk over the medium term.
Negative Operating Cash FlowConsistent negative operating cash flow requires external funding to sustain operations and R&D. Reliance on financing increases dilution and constrains strategic choices, and if capital markets tighten the company may need to slow investment or commercialization, impeding long-term scaling.
Very Small Operating ScaleA seven-person team limits capacity for regulatory, clinical, and commercial rollouts in complex healthcare markets. Limited human resources can slow product iterations, trials, and sales cycles, making it harder to convert technical capability into sustainable revenue over the next several months.
Neola Medical AB News
NEOLA FAQ
What was Neola Medical AB’s price range in the past 12 months?
Neola Medical AB lowest stock price was kr0.58 and its highest was kr2.94 in the past 12 months.
What is Neola Medical AB’s market cap?
Neola Medical AB’s market cap is kr122.23M.
When is Neola Medical AB’s upcoming earnings report date?
Neola Medical AB’s upcoming earnings report date is Aug 20, 2026 which is in 61 days.
How were Neola Medical AB’s earnings last quarter?
Neola Medical AB released its earnings results on May 19, 2026. The company reported -kr0.044 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.044.
Is Neola Medical AB overvalued?
According to Wall Street analysts Neola Medical AB’s price is currently Overvalued.
Does Neola Medical AB pay dividends?
Neola Medical AB does not currently pay dividends.
What is Neola Medical AB’s EPS estimate?
Neola Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neola Medical AB have?
Neola Medical AB has 124,720,375 shares outstanding.
What happened to Neola Medical AB’s price movement after its last earnings report?
Neola Medical AB reported an EPS of -kr0.044 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.863%.
Which hedge fund is a major shareholder of Neola Medical AB?
Currently, no hedge funds are holding shares in SE:NEOLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neola Medical AB
Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. This device facilitates ongoing lung function monitoring and generates immediate alerts for critical, life-threatening complications. It achieves this by accurately tracking changes in lung volume and oxygen gas concentration. The ultimate goal of NEOLA is to enhance intensive care and promote healthier outcomes for infants born preterm. The company, formerly known as GPX Medical AB, officially changed its name to Neola Medical AB (publ) in June 2022. Neola Medical AB (publ) was established in 2016 and is headquartered in Lund, Sweden.
Technical Analysis
―
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Nosa Plugs AB
―
Arcoma AB
―